Mark G. Erlander

16.2k total citations · 6 hit papers
152 papers, 11.5k citations indexed

About

Mark G. Erlander is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Mark G. Erlander has authored 152 papers receiving a total of 11.5k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 67 papers in Cancer Research and 36 papers in Molecular Biology. Recurrent topics in Mark G. Erlander's work include Cancer Genomics and Diagnostics (41 papers), Breast Cancer Treatment Studies (22 papers) and Colorectal Cancer Treatments and Studies (18 papers). Mark G. Erlander is often cited by papers focused on Cancer Genomics and Diagnostics (41 papers), Breast Cancer Treatment Studies (22 papers) and Colorectal Cancer Treatments and Studies (18 papers). Mark G. Erlander collaborates with scholars based in United States, United Kingdom and New Zealand. Mark G. Erlander's co-authors include Allan J. Tobin, Sophie Feldblum, Niranjala J.K. Tillakaratne, Dennis C. Sgroi, Allan J. Tobin, Xiaojun Ma, Timothy W. Lovenberg, Neela Patel, Ranelle Salunga and Jayashree Pyati and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Mark G. Erlander

150 papers receiving 11.2k citations

Hit Papers

Two genes encode distinct glutamate decarboxylases 1991 2026 2002 2014 1991 2003 1999 1999 1993 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Two genes encode distinct glutamate decarboxylases
    1991 1.0k citations Mark G. Erlander, Niranjala J.K. Tillakaratne et al. profile →
  2. Gene expression profiles of human breast cancer progression
    2003 673 citations Xiaojun Ma, Ranelle Salunga et al. profile →
  3. Cloning and Functional Expression of the Human Histamine H3Receptor
    1999 612 citations Michael R. Jackson, Mark G. Erlander et al. profile →
  4. Gene expression profiles of laser-captured adjacent neuronal subtypes
    1999 605 citations Ranelle Salunga, Mark G. Erlander et al. profile →
  5. A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms
    1993 590 citations Mark G. Erlander et al. profile →
  6. Gene expression profiling of the tumor microenvironment during breast cancer progression
    2009 488 citations Xiaojun Ma, Sonika Dahiya et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark G. Erlander United States 51 4.7k 2.6k 2.5k 2.4k 1.8k 152 11.5k
Fumiaki Tanaka Japan 68 9.2k 2.0× 2.9k 1.1× 3.1k 1.3× 3.4k 1.4× 801 0.4× 360 15.8k
Kazuki Nakao Japan 58 9.6k 2.0× 1.7k 0.7× 1.5k 0.6× 2.3k 1.0× 1.7k 0.9× 221 15.7k
Charles D. Stiles United States 65 11.0k 2.3× 3.0k 1.1× 3.1k 1.3× 1.9k 0.8× 2.1k 1.2× 139 18.0k
Teresa L. Yang‐Feng United States 45 8.0k 1.7× 3.3k 1.3× 1.0k 0.4× 1.8k 0.7× 2.2k 1.2× 104 13.6k
Harley I. Kornblum United States 59 6.7k 1.4× 2.1k 0.8× 2.0k 0.8× 2.5k 1.0× 757 0.4× 158 11.7k
Azad Bonni United States 57 13.8k 2.9× 2.8k 1.1× 1.8k 0.7× 3.5k 1.4× 1.9k 1.0× 131 19.1k
Motoya Katsuki Japan 55 6.4k 1.3× 1.8k 0.7× 1.5k 0.6× 2.1k 0.9× 1.6k 0.9× 160 12.0k
Grigori Enikolopov United States 56 6.4k 1.3× 1.6k 0.6× 1.2k 0.5× 3.0k 1.2× 1.2k 0.7× 148 16.1k
Heidi Phillips United States 60 11.1k 2.3× 2.7k 1.0× 3.4k 1.4× 8.0k 3.3× 1.8k 1.0× 140 23.3k
Patrick Mehlen France 61 8.8k 1.9× 1.9k 0.7× 1.3k 0.5× 4.1k 1.7× 546 0.3× 162 12.8k

Countries citing papers authored by Mark G. Erlander

Since Specialization
Citations

This map shows the geographic impact of Mark G. Erlander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark G. Erlander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark G. Erlander more than expected).

Fields of papers citing papers by Mark G. Erlander

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark G. Erlander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark G. Erlander. The network helps show where Mark G. Erlander may publish in the future.

Co-authorship network of co-authors of Mark G. Erlander

This figure shows the co-authorship network connecting the top 25 collaborators of Mark G. Erlander. A scholar is included among the top collaborators of Mark G. Erlander based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark G. Erlander. Mark G. Erlander is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Patterson, Jesse C., Andreas Varkaris, Peter J.P. Croucher, et al.. (2022). Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling. Cancer Research. 83(2). 219–238. 12 indexed citations
2.
Zeidan, Amer M., Maya Ridinger, Tara L. Lin, et al.. (2020). A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clinical Cancer Research. 26(23). 6132–6140. 57 indexed citations
3.
Wang, Xiaolong, Bingsheng Li, Anna Ciotkowska, et al.. (2020). Onvansertib, a polo-like kinase 1 inhibitor, inhibits prostate stromal cell growth and prostate smooth muscle contraction, which is additive to inhibition by α1-blockers. European Journal of Pharmacology. 873. 172985–172985. 18 indexed citations
4.
5.
Husain, Hatim, Vladislava O. Melnikova, Karena Kosco, et al.. (2017). Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine. Clinical Cancer Research. 23(16). 4716–4723. 106 indexed citations
6.
Franovic, Aleksandra, Victoria M. Raymond, Mark G. Erlander, & Karen L. Reckamp. (2017). Urine test for EGFR analysis in patients with non-small cell lung cancer. Journal of Thoracic Disease. 9(S13). S1323–S1331. 17 indexed citations
7.
Chapman, Judith‐Anne W., Dennis C. Sgroi, Paul E. Goss, et al.. (2016). Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14. Breast Cancer Research and Treatment. 157(1). 101–108.
8.
Hyman, David M., Eli L. Diamond, Cecile Rose T. Vibat, et al.. (2014). Prospective Blinded Study of BRAF V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. Cancer Discovery. 5(1). 64–71. 84 indexed citations
9.
Zhang, Yi, Catherine A. Schnabel, Brock E. Schroeder, et al.. (2013). Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence. Clinical Cancer Research. 19(15). 4196–4205. 163 indexed citations
10.
Sgroi, Dennis C., Erin Carney, Elizabeth Zarrella, et al.. (2013). Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker. JNCI Journal of the National Cancer Institute. 105(14). 1036–1042. 153 indexed citations
11.
Šestak, Ivana, Mitch Dowsett, Dennis C. Sgroi, et al.. (2013). Comparison of Five Different Scores for the Prediction of Late Recurrence for Oestrogen Receptor-Positive Breast Cancer. Annals of Oncology. 24. iii29–iii29. 4 indexed citations
12.
Kerr, Sarah E., Catherine A. Schnabel, Peggy Sullivan, et al.. (2012). Multisite Validation Study to Determine Performance Characteristics of a 92-Gene Molecular Cancer Classifier. Clinical Cancer Research. 18(14). 3952–3960. 66 indexed citations
13.
Schnabel, Catherine A. & Mark G. Erlander. (2012). Gene expression-based diagnostics for molecular cancer classification of difficult to diagnose tumors. Expert Opinion on Medical Diagnostics. 6(5). 407–419. 6 indexed citations
14.
Weiss, Lawrence M., Peiguo Chu, Brock E. Schroeder, et al.. (2012). Blinded Comparator Study of Immunohistochemical Analysis versus a 92-Gene Cancer Classifier in the Diagnosis of the Primary Site in Metastatic Tumors. Journal of Molecular Diagnostics. 15(2). 263–269. 54 indexed citations
15.
McDermott, Ultan, A. John Iafrate, Shyamala Maheswaran, et al.. (2009). Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-α Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase Inhibitors. Cancer Research. 69(9). 3937–3946. 83 indexed citations
16.
Ma, Xiaojun, Ranelle Salunga, Sonika Dahiya, et al.. (2008). A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer. Clinical Cancer Research. 14(9). 2601–2608. 227 indexed citations
17.
Peterson, Karin S., Jing-Feng Huang, Jessica Zhu, et al.. (2004). Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. Journal of Clinical Investigation. 113(12). 1722–1733. 186 indexed citations
18.
Peterson, Karin S., Jing-Feng Huang, Jessica Zhu, et al.. (2004). Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. Journal of Clinical Investigation. 113(12). 1722–1733. 197 indexed citations
19.
Greif, Karen F., Mark G. Erlander, Niranjala J.K. Tillakaratne, & Allan J. Tobin. (1991). Postnatal expression of glutamate decarboxylases in developing rat cerebellum. Neurochemical Research. 16(3). 235–242. 69 indexed citations
20.
Erlander, Mark G., Niranjala J.K. Tillakaratne, Susana González, et al.. (1987). Humans and rats contain a single gene encoding brain glutamic acid decarboxylase. The Society for Neuroscience Abstracts. 13(2). 857. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fumiaki Tanaka Breakdown of academic impact, for papers by Kazuki Nakao Breakdown of academic impact, for papers by Charles D. Stiles Breakdown of academic impact, for papers by Teresa L. Yang‐Feng Breakdown of academic impact, for papers by Harley I. Kornblum Breakdown of academic impact, for papers by Azad Bonni Breakdown of academic impact, for papers by Motoya Katsuki Breakdown of academic impact, for papers by Grigori Enikolopov Breakdown of academic impact, for papers by Heidi Phillips Breakdown of academic impact, for papers by Patrick Mehlen
Rankless by CCL
2026